Immunotherapy showed promising antileukemia activity in pediatric patients

April 7, 2013, American Association for Cancer Research

Researchers using patients' own immune cells in an immunotherapy approach called "anti-CD19 chimeric antigen receptor (CAR) T-cell therapy," achieved responses in children whose acute lymphocytic leukemia (ALL) had returned after a bone marrow transplant, according to preliminary results presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10.

"Anti-CD19 CAR T-cell therapy using patients' own is a completely new way of treating ," said Daniel W. Lee, M.D., assistant clinical investigator in the Pediatric Oncology Branch of the . "It is not chemotherapy; therefore, it has a different side effect profile—we hope better tolerated. In the limited number of post- we have treated so far, we're getting acceptable toxicities, and we're not seeing graft-versus-host disease."

More than 95 percent of children initially diagnosed with ALL achieve , but a significant number of them relapse, according to Lee. Once they relapse, the prognosis is poor, with ALL accounting for the most deaths from cancer among children.

Other research teams are testing anti-CD19 CAR T-cell therapy in children with ALL that has returned after a bone marrow transplant, according to Lee. However, whether they are using immune cells from the , or collecting and preparing the patient's cells, the process is lengthy.

"Often these children with relapsed ALL don't have that kind of time to wait," Lee said. "We wanted something that could be done in a more timely manner. We decided to collect the immune cells, which are called T cells, directly from the patients, even though they'd had bone marrow transplants."

The first three patients in the phase I trial had undergone a previous bone marrow transplant, although the trial is also open to patients who have never had a transplant. One patient had B-cell lymphoma and the other two had ALL.

The researchers collected T cells from the patients and modified them in the laboratory so that they would attach to a protein expressed by the leukemia cells, called CD19, and attack the cancers. The number of modified T cells, now called anti-CD19 CAR T cells, was expanded in the laboratory before they were returned to the patients.

The results so far indicate that this approach is a feasible and active treatment for pediatric patients with ALL, even those who relapse after a bone marrow transplant, according to Lee. One patient had a complete response and a second had a transient complete response, with minimal residual disease remaining. The lone lymphoma patient did not respond.

Cell expansion was robust. "We were able to get very good expansion—on average about 60-fold expansion of these cells during the 11-day culture period," Lee said. "And we were able to insert the receptor, the anti-CD19 CAR, into those with good efficiency."

One patient did not produce a sufficient number of cells, which was likely related to recent intensive chemotherapy and resultant low T-cell count, according to Lee. Despite this, the few cells the patient did receive expanded dramatically and the patient temporarily achieved remission.

Lee and colleagues continue to test this approach in patients whose disease has returned after, or is refractory to, standard treatments whether or not they have had a transplant.

"We think that the children who have never had a transplant might experience different toxicities," said Lee. "Our first patient enrolled in this arm of the trial had never achieved disease remission after her initial diagnosis of ALL despite intensive chemotherapy. Strikingly, anti-CD19 CAR T-cell therapy resulted in the complete clearance of any detectable leukemia in this patient, and we were able to send her back to her primary oncologists for a ."

Lee's research was partially funded by the St. Baldrick's Foundation.

Explore further: Bone marrow transplant eliminates signs of HIV infection

Related Stories

Bone marrow transplant eliminates signs of HIV infection

July 26, 2012
Two men with longstanding HIV infections no longer have detectable HIV in their blood cells following bone marrow transplants. The virus was easily detected in blood lymphocytes of both men prior to their transplants but ...

No survival advantage with peripheral blood stem cells versus bone marrow

October 19, 2012
(Medical Xpress)—Claudio Anasetti, M.D., chair of the Department of Blood & Marrow Transplant at Moffitt Cancer Center, and colleagues from 47 research sites in the Blood and Marrow Transplant Clinical Trials Network conducted ...

Immune therapy shows early promise for advanced leukemia

March 20, 2013
(HealthDay)—An experimental therapy that targets the immune system might offer a new way to treat an often deadly form of adult leukemia, a preliminary study suggests.

T-cell therapy eradicates an aggressive leukemia in two children

March 25, 2013
Two children with an aggressive form of childhood leukemia had a complete remission of their disease-showing no evidence of cancer cells in their bodies-after treatment with a novel cell therapy that reprogrammed their immune ...

New half-match bone marrow transplant procedure yields promising outcomes for cancer patients

September 1, 2011
Half-matched bone marrow or stem cell transplants for blood cancer patients have typically been associated with disappointing clinical outcomes. However, a clinical trial conducted at the Kimmel Cancer Center at Jefferson ...

Bone marrow and blood stem cell transplant survival rates equal, when donor is unrelated to patient

December 12, 2011
Patients who receive a blood stem cell transplant from a donor outside of their family to treat leukemia and other blood diseases are more likely to have graft failure but less likely to experience graft-versus-host disease, ...

Recommended for you

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.